Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 67 (4), e28199

Chimeric Antigen Receptor T-cell Therapy in Patients With Neurologic Comorbidities


Chimeric Antigen Receptor T-cell Therapy in Patients With Neurologic Comorbidities

Jeremy D Rubinstein et al. Pediatr Blood Cancer.


Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

Keywords: CAR-T; cellular therapy; neurotoxicity; pre-B ALL.

Similar articles

See all similar articles



    1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
    1. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-3331.
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. NEJM. 2018;378:439-448.
    1. Neelapu SS, Tummala S, Kebriae P, et al. Chimeric antigen receptor T-cell therapy- assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
    1. Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokines release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295-2306.

LinkOut - more resources